Epidermal growth factor receptor mutations
US7981605B2 · kind B2 · utility
5Cited by
2References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 23, 2006 |
| Grant date | Jul 19, 2011 |
| Priority date | — |
| Expiry date | Aug 23, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3′-kinase (“Pl3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant Pl3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.